The 2009 H 1N 1 influenza pandemic demonstrated the significance of a global health threat to human beings. Although pandemic H 1N 1 vaccines have been rapidly developed, passive serotherapy may offer superior immedia...The 2009 H 1N 1 influenza pandemic demonstrated the significance of a global health threat to human beings. Although pandemic H 1N 1 vaccines have been rapidly developed, passive serotherapy may offer superior immediate protection against infections in children, the elderly and immune-compromised patients during an influenza pandemic. Here, we applied a novel strategy based on Epstein-Barr virus （EBV）-immortalized peripheral blood memory B cells to screen high viral neutralizing monoclonal antibodies （MAbs） from individuals vaccinated with the 2009 pandemic H1N1 vaccine PANFLU.1. Through a massive screen of 13 090 immortalized memory B-cell clones from three selected vaccinees, seven MAbs were identified with both high viral neutralizing capacities and hemagglutination inhibition （HAl） activities against the 2009 pandemic H 1N 1 viruses. These MAbs may have important clinical implications for passive serotherapy treatments of infected patients with severe respiratory syndrome, especially children, the elderly and immunodeficient individuals. Our successful strategy for generating high-affinity MAbs from EBV-immortalized peripheral blood memory B ceils may also be applicable to other infectious or autoimmune diseases.展开更多
The epidemic of corona virus disease 2019(COVID-19)caused by severe acute respiratory syndrome Coronavirus 2 and its variants of concern(VOCs)has been ongoing for over 3 years.Antibody therapies encompassing convalesc...The epidemic of corona virus disease 2019(COVID-19)caused by severe acute respiratory syndrome Coronavirus 2 and its variants of concern(VOCs)has been ongoing for over 3 years.Antibody therapies encompassing convalescent plasma,hyperimmunoglobulin,and neutralizing monoclonal antibodies(mAbs)applied in passive immunotherapy have yielded positive outcomes and played a crucial role in the early COVID-19 treatment.In this review,the development path,action mechanism,clinical research results,challenges,and safety profile associated with the use of COVID-19 convalescent plasma,hyperimmunoglobulin,and mAbs were summarized.In addition,the prospects of applying antibody therapy against VOCs was assessed,offering insights into the coping strategies for facing new infectious disease outbreaks.展开更多
文摘The 2009 H 1N 1 influenza pandemic demonstrated the significance of a global health threat to human beings. Although pandemic H 1N 1 vaccines have been rapidly developed, passive serotherapy may offer superior immediate protection against infections in children, the elderly and immune-compromised patients during an influenza pandemic. Here, we applied a novel strategy based on Epstein-Barr virus （EBV）-immortalized peripheral blood memory B cells to screen high viral neutralizing monoclonal antibodies （MAbs） from individuals vaccinated with the 2009 pandemic H1N1 vaccine PANFLU.1. Through a massive screen of 13 090 immortalized memory B-cell clones from three selected vaccinees, seven MAbs were identified with both high viral neutralizing capacities and hemagglutination inhibition （HAl） activities against the 2009 pandemic H 1N 1 viruses. These MAbs may have important clinical implications for passive serotherapy treatments of infected patients with severe respiratory syndrome, especially children, the elderly and immunodeficient individuals. Our successful strategy for generating high-affinity MAbs from EBV-immortalized peripheral blood memory B ceils may also be applicable to other infectious or autoimmune diseases.
文摘The epidemic of corona virus disease 2019(COVID-19)caused by severe acute respiratory syndrome Coronavirus 2 and its variants of concern(VOCs)has been ongoing for over 3 years.Antibody therapies encompassing convalescent plasma,hyperimmunoglobulin,and neutralizing monoclonal antibodies(mAbs)applied in passive immunotherapy have yielded positive outcomes and played a crucial role in the early COVID-19 treatment.In this review,the development path,action mechanism,clinical research results,challenges,and safety profile associated with the use of COVID-19 convalescent plasma,hyperimmunoglobulin,and mAbs were summarized.In addition,the prospects of applying antibody therapy against VOCs was assessed,offering insights into the coping strategies for facing new infectious disease outbreaks.
